Importantly, our data suggest that positive Vimentin expression may serve as a biomarker to predict a poor prognosis in cervical cancer patients and provides important insights into the design of novel therapeutic strategies to treat cervical cancer patients. This evidence concerns the gene VIM and cervical cancer.